PT-141 Evidence Guide
PT-141 (bremelanotide) is FDA-approved for hypoactive sexual desire disorder in premenopausal women (Vyleesi), providing a regulatory anchor for sexual health research. Phase 3 data in women is solid; male sexual dysfunction data is earlier-stage. For melanocortin-pathway sexual health research, this is the best-evidenced starting point.
Our Take
PT-141 (bremelanotide) is FDA-approved for hypoactive sexual desire disorder in premenopausal women (Vyleesi), providing a regulatory anchor for sexual health research. Phase 3 data in women is solid; male sexual dysfunction data is earlier-stage. For melanocortin-pathway sexual health research, this is the best-evidenced starting point.
- Evidence context
- Hypoactive sexual desire disorder (women), sexual dysfunction research, melanocortin pathway
- Evidence grade
- Level A
- Confidence
- High
- Reference context
- Regulatory label reference: 1.75mg subcutaneous, administered 45 minutes before sexual activity (approved dosing)
Benefits and Evidence
- Female Sexual Desire: Level A, includes human evidence - FDA-approved based on Phase 3 trials showing statistically significant increase in sexual desire and reduction in distress related to low sexual desire in premenopausal women.
- Male Erectile Function: Level B, includes human evidence - Clinical trials demonstrated efficacy in male erectile dysfunction, including cases non-responsive to PDE5 inhibitors. Not FDA-approved for this indication.
- Nausea: Level A, includes human evidence - Nausea is the most common side effect, affecting ~40% of users. Usually mild to moderate and transient.
Side Effects and Warnings
- Nausea (40%)
- Flushing
- Headache
- Injection site reactions
- Transient blood pressure increase
- Hyperpigmentation with repeated use
- Contraindicated in uncontrolled hypertension
- May cause transient BP increase
Research Dosage References
- <strong>Subcutaneous injection (FDA-approved)</strong> - 1.75 mg - As needed, at least 45 min before activity - Vyleesi auto-injector. No more than one dose per 24 hours, no more than 8 doses per month.
- <strong>Subcutaneous (research)</strong> - 0.5-2 mg - As needed - Lower doses may reduce nausea while maintaining efficacy.
Mechanism of Action
PT-141 works through melanocortin receptor activation: 1. MC4R agonism: Primarily activates melanocortin-4 receptors in the hypothalamus, the brain region controlling sexual behavior. 2. Central mechanism: Unlike PDE5 inhibitors (Viagra), works through the CNS rather than directly on blood vessels. 3. Dopamine modulation: May increase dopamine activity in brain regions associated with sexual motivation. 4. Both sexes: Mechanism is not sex-specific, showing effects in both males and females in clinical trials. 5. Desire vs. function: Specifically targets sexual desire rather than mechanical function.
Legal Status
FDA-approved as Vyleesi for HSDD in premenopausal women (2019). Prescription required. Available by auto-injector. Not approved for male sexual dysfunction. Also available as a research peptide.
Primary Sources
- Bremelanotide for Female Sexual Dysfunction (RECONNECT Phase 3). Obstet Gynecol, 2019.
- Bremelanotide for male sexual dysfunction. Int J Impot Res, 2006.
Quick Answers
Where is the strongest evidence for PT-141?
PT-141 (bremelanotide) is FDA-approved for hypoactive sexual desire disorder in premenopausal women (Vyleesi), providing a regulatory anchor for sexual health research. Phase 3 data in women is solid; male sexual dysfunction data is earlier-stage. For melanocortin-pathway sexual health research, this is the best-evidenced starting point. Evidence context: Hypoactive sexual desire disorder (women), sexual dysfunction research, melanocortin pathway.
What are the main side effects of PT-141?
PT-141 side effects and warning signals include Nausea (40%), Flushing, Headache, Injection site reactions, and Transient blood pressure increase.
What evidence level is PT-141?
PT-141 is rated Level A; the listed research status is FDA Approved.